{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hwang H"],"funding":["Seoul National University Bundang Hospital"],"pagination":["366-376"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8925945"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(2)"],"pubmed_abstract":["<h4>Background/aims</h4>Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF.<h4>Methods</h4>This multicenter retrospective cohort study investigated 338 patients treated with pirfenidone between July 2012 and March 2018. Demographics, pulmonary function, mortality, and pirfenidone-related adverse events were also investigated. Efficacy was analyzed according to pirfenidone dose and disease severity using linear mixed-effects models to assess the annual decline rate of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO).<h4>Results</h4>The mean %FVCpredicted and %DLCOpredicted values were 72.6% ± 13.1% and 61.4% ± 17.9%, respectively. The mean duration of pirfenidone treatment was 16.1 ± 9.0 months. In the standard dose (1,800 mg/day) group, the mean %FVCpredicted was -6.56% (95% confidence interval [CI], -9.26 to -3.87) per year before, but -4.43% (95% CI, -5.87 to -3.00) per year after treatment with pirfenidone. In the non-standard lower dose group, the mean %FVCpredicted was -4.96% (95% CI, -6.82 to -3.09) per year before, but -1.79% (95% CI, -2.75 to -0.83) per year after treatment with pirfenidone. The FVC decline rate was significantly reduced, regardless of the Gender-Age-Physiology (GAP) stage. Adverse events and mortality were similar across dose groups; however, they were more frequent in GAP stages II-III than in the stage I group.<h4>Conclusion</h4>The effect of pirfenidone on reducing disease progression of IPF persisted even with a consistently lower dose of pirfenidone."],"journal":["The Korean journal of internal medicine"],"pubmed_title":["Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study."],"pmcid":["PMC8925945"],"funding_grant_id":["06-2019-001"],"pubmed_authors":["Cho YJ","Hwang H","Lee JK","Lee CT","Kim YW","Lee YJ","Choi SM","Yoon HI","Lee JH","Park JS"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study.","description":"<h4>Background/aims</h4>Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF.<h4>Methods</h4>This multicenter retrospective cohort study investigated 338 patients treated with pirfenidone between July 2012 and March 2018. Demographics, pulmonary function, mortality, and pirfenidone-related adverse events were also investigated. Efficacy was analyzed according to pirfenidone dose and disease severity using linear mixed-effects models to assess the annual decline rate of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO).<h4>Results</h4>The mean %FVCpredicted and %DLCOpredicted values were 72.6% ± 13.1% and 61.4% ± 17.9%, respectively. The mean duration of pirfenidone treatment was 16.1 ± 9.0 months. In the standard dose (1,800 mg/day) group, the mean %FVCpredicted was -6.56% (95% confidence interval [CI], -9.26 to -3.87) per year before, but -4.43% (95% CI, -5.87 to -3.00) per year after treatment with pirfenidone. In the non-standard lower dose group, the mean %FVCpredicted was -4.96% (95% CI, -6.82 to -3.09) per year before, but -1.79% (95% CI, -2.75 to -0.83) per year after treatment with pirfenidone. The FVC decline rate was significantly reduced, regardless of the Gender-Age-Physiology (GAP) stage. Adverse events and mortality were similar across dose groups; however, they were more frequent in GAP stages II-III than in the stage I group.<h4>Conclusion</h4>The effect of pirfenidone on reducing disease progression of IPF persisted even with a consistently lower dose of pirfenidone.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-05T15:58:04.212Z","creation":"2025-04-05T15:58:04.212Z"},"accession":"S-EPMC8925945","cross_references":{"pubmed":["34293852"],"doi":["10.3904/kjim.2020.559"]}}